Uncategorized
Santen initiates phase 2a study of DE-122 for wet AMD
Santen has initiated a phase 2a clinical study of the efficacy and safety of intravitreal injections of DE-122 for the treatment of wet age-related macular degeneration, according to a joint press release from Santen and Tracon Pharmaceuticals.The randomized controlled trial will assess DE-122 in combination with Lucentis (ranibizumab, Genentech) compared with ranibizumab alone in patients with wet AMD. The initiation of the study will trigger a $7 million milestone payment from Santen to Tracon, the release said.